F-Prime Capital

F-Prime Capital is a Cambridge, Massachusetts-based venture capital firm that serves as the principal venture capital vehicle for investments tied to Fidelity Investments, one of the world's largest financial services companies, investing in healthcare, biotech, and technology companies at seed through Series B stages. The firm manages capital independently from Fidelity's mutual fund and asset management operations, applying a long-term, patient capital approach that reflects Fidelity's institutional DNA. F-Prime Capital focuses primarily on healthcare and life sciences, backing clinical-stage biotech companies, digital health platforms, and healthcare infrastructure businesses, alongside a technology portfolio covering enterprise software and developer tools. The firm invests with initial checks from $5 million to $25 million and brings the resources, relationships, and network of Fidelity's global financial services franchise to portfolio companies. Portfolio companies include Appian, the low-code process automation platform that completed a Nasdaq IPO in 2017; Cardiogram, the heart health monitoring and AI analysis platform; Epigenomics, a molecular diagnostics company; and Syapse, the real-world evidence and precision medicine data platform. Beyond its original investments, the portfolio includes additional healthcare technology, biotech, and enterprise software companies.